Primary Cutaneous Follicular Helper T-Cell Lymphoma: A Clinicopathological Study of Six Cases and Review of the Literature.

J Cutan PatholJul 21, 2026 (epub)
Case ReportDermatologyOncology (Medical)Open access

Jianlan Xie, Zhu Li, Xiaoge Zhou et al.

✦ AI-curated · Sources linked

Case in brief

This study presents six cases of primary cutaneous follicular helper T-cell lymphoma (pcTFH-L), characterized by localized skin lesions in patients aged 42 to 75 years, without systemic symptoms. Histopathological examination revealed dermal infiltration by atypical lymphocytes, with a nodular or diffuse pattern. All cases expressed CD4 and multiple TFH markers, with variable clinical outcomes, including stable disease and complete remission, while two patients experienced severe complications.

Diagnostic / clinical pearl

The consistent expression of PD-1, ICOS, and CXCL13 in pcTFH-L is crucial for accurate diagnosis and differentiation from other cutaneous T-cell lymphoproliferative disorders.

Why it matters

Understanding the immunophenotypic profile of pcTFH-L can aid clinicians in diagnosing this rare lymphoma and managing patient outcomes effectively.

Source

Published in J Cutan Pathol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Dermatology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.